SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending as investors react to a significant sell-off following disappointing revenue guidance and projections of a steep decline in the Chinese market. Community sentiment is deeply divided, with some investors viewing the price drop as a rare entry point for a long-term 'dividend aristocrat' play, while others warn of a 'value trap' due to stalled growth and ongoing concerns regarding management's turnaround strategy.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing high volatility as investors react to mixed quarterly earnings and the companys ongoing struggles with trade tariffs and a challenging housing market. While the community remains deeply divided, with many debating whether the stock is a long-term value opportunity or a failing luxury retailer, the stock continues to see significant short interest and intense speculation regarding future legal developments surrounding trade policy.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened community discussion and bullish sentiment following a significant stake acquisition by Bill Ackman, driving speculation about a potential turnaround and a massive short squeeze. Investors are closely monitoring key technical resistance levels while debating the impact of upcoming debt obligations and the company's long-term strategy.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending due to the announcement of a massive multi-year AI infrastructure contract, which has sparked intense community debate regarding its low-float potential for a significant squeeze. Investors are actively discussing the stock's future, weighing the deal's long-term value against frustrations over current volume, price action, and perceived manipulation.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune is trending as investors debate its potential for volatile, high-percentage swings characteristic of low-float Chinese IPOs, drawing comparisons to previous market runners. While some traders are aggressively positioning for a rapid squeeze fueled by lock-up dynamics, many participants are cautioning others about the significant risks associated with its history of extreme volatility and pump-and-dump patterns.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened retail interest as traders monitor its history of volatile, low-float runs and speculate on the potential for a short squeeze. Community discussion is heavily focused on the stock's lack of available shares to borrow, extreme cost-to-borrow fees, and comparisons to previous multi-bagger rallies, with many debating whether this represents a genuine reversal or a potential liquidity trap.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF is trending as investors seek exposure to the anticipated SpaceX IPO and broader space sector growth. While some community members are optimistic about its focus on space technology and satellite infrastructure, others are actively debating its low assets under management and comparing its potential performance and strategy to other existing space-linked investment vehicles.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense market speculation driven by recurring buyout rumors involving major technology and aerospace players like SpaceX and Amazon. Investors are actively debating the potential valuation of the company's critical spectrum assets and satellite infrastructure, fueled by anticipation of upcoming earnings and recent industry partnerships.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating buzz as investors speculate on a potential breakout driven by its low circulating supply and market cap, with community members actively discussing a possible resurgence in the NFT sector. While some are optimistic about the project's long-term utility and future exchange listings, others remain skeptical, highlighting volatility and the need for sustained trading volume.

ElizaAgentic

ElizaAgentic is experiencing a surge in momentum and heightened social media activity as traders emphasize the asset's clean technical structure and bullish price continuation. The community is actively drawing parallels to broader market trends across major chains, fueling widespread speculation on its potential trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg.</li><li>SGMO slipped after reporting a Q4 loss per share of $0.11 versus the expected loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.</li><li>PHR declined after cutting its FY27 revenue outlook to $510 million-$520 million from $545 million-$559 million, below analyst expectations of $552.1 million.</li></ul>Shares of PepGen (PEPG), Sangamo Therapeutics (SGMO), and Phreesia (PHR) were among the top premarket losers on Tuesday as investors reacted to muted functional trial results, a wider-than-expected loss, and a revenue outlook cut, prompting analyst downgrades.In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%.<h2 class="st-heading-2">PepGen Trial Shows No Functional Gains At Low Dose</h2>PepGen reported results from the lowest-dose cohort in its Phase 2 Freedom 2 study of PGN-EDODM1 in patients with myotonic dystrophy type 1, with investors focusing on the lack of functional improvement at the starting dose.The company said the therapy was generally well tolerated, with all adverse events mild or moderate and no serious adverse events reported. However, the company also said patients showed “no meaningful improvements” in walking speed or hand strength at the starting 5 mg/kg dose of PGN-EDODM1.PepGen said patients receiving the treatment showed an average 7.3% improvement on a disease-related molecular metric, compared with 6.8% in placebo patients, rising to 22.9% after excluding one outlier. The company expects results from the higher 10 mg/kg cohort in the second half of 2026, with cash expected to support operations into the second half of 2027.<h2 class="st-heading-2">Sangamo Loss Widens As Funding Outlook Weighs</h2>Sangamo Therapeutics reported a fourth-quarter (Q4) loss per share of $0.11, wider than analyst expectations for a loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.The company highlighted progress in its Fabry disease gene therapy program, saying it is “well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway” following positive topline results from the registrational STAAR study.However, sentiment appeared pressured after the company said its 2026 expense outlook is “subject to our ability to secure adequate additional funding for our current operating plan.” Sangamo expects non-GAAP operating expenses of $110 million to $120 million in 2026.<h2 class="st-heading-2">Phreesia Guidance Cut Triggers Broker Downgrades</h2>Phreesia reported Q4 revenue of $127.1 million, slightly above analyst expectations of $126.6 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $29.4 million from $16.4 million a year earlier.Shares fell after the company lowered its fiscal 2027 revenue outlook to $510 million to $520 million, down from $545 million to $559 million, and below analyst expectations of $552.1 million. The company said, “Network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December.”Following the guidance cut, Baird downgraded the stock to ‘Neutral’ from ‘Outperform’ and reduced its price target to $10 from $25, saying “the magnitude of the follow-on impact exceeded expectations.” Truist Securities also downgraded the stock to ‘Hold’ from ‘Buy’ and lowered its price target to $11 from $24, citing “the meaningful reduction to the revenue outlook.”<h2 class="st-heading-2">How Do Retail Traders Feel About PEPG, SGMO And PHR?</h2>On Stocktwits, retail sentiment for PEPG, SGMO and PHR was ‘extremely bullish’ amid ‘extremely high’ message volume.Over the past year, PEPG has risen 186%, while SGMO has fallen 63% and PHR has declined 56%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-below-buffett-entry-price-first-revenue-decline-30-years-ai/cZEPohoRINz">UNH Stock Slides Back Below Warren Buffett’s Entry Price As Annual Revenue Faces First Decline In 30 Years — AI May Be Long-Term Fix</a>

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.  In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%

Equity

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

Sangamo Therapeutics Q4 Earnings Call Highlights

Sangamo Therapeutics (NASDAQ:SGMO) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight progress across its Fabry disease and neurology pipelines, while...

Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) issued its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.12). Sangamo Therapeutics had a negative net margin of 331.28...

Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.read more...

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

Adherex Technologies (FENC) delivered earnings and revenue surprises of -540.00% and -7.94%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 33,200,460 shares, a growth...

FY2030 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report issued on Tuesday...

$SGMO Q4 &#39;25 Earnings Results &amp; Recap

Sangamo Therapeutics expects GAAP total operating expenses for 2026 to be approximately $120M to $140M, and its current funding is sufficient to support planned operations into the third quarter of 2026, subject to securing additional funding.

Stocktwits

Sangamo Therapeutics Inc

 Q4 '25 Earnings Results & Recap

Sangamo Therapeutics expects GAAP total operating expenses for 2026 to be approximately $120M to $140M, and its current funding is sufficient to support planned operations into the third quarter of 2026, subject to securing additional funding.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.00	--	--	N/A
Q4 '25	$0.01	-$0.11	-1318.84%	MISSED
Q3 '25	-$0.00	-$0.11	-24344.44%	MISSED
Q2 '25	-$0.01	-$0.08	-694.68%	MISSED
Q1 '25	-$0.12	-$0.14	-19.37%	MISSED

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest SGMO News

SGMOSangamo Therapeutics Inc